Sten Gunnar Otto Skolling
Director/Board Member presso CHORDATE MEDICAL HOLDING AB
Profilo
Sten Gunnar Otto Skolling currently works at Pharmor AB, as Chairman & Chief Executive Officer, Isles of Wines AB, as Chief Executive Officer & Director, Umecrine AB, as Chairman, Chordate Medical Holding AB, as Vice Chairman from 2023, Athera Biotechnologies AB, as Director, Lipidor AB, as Director from 2020, Biochromix AB, as Director, Venture Cup Ost, as Director, Stockholm Biotechbuilders Association, as Director, Nanexa AB, as Director-Business Development, RespiNor AS, as Director, Bactaviva AB, as Director, and Asarina Pharma AB, as Chief Business Officer from 2018.
Mr. Skolling also formerly worked at KCIF Fund Management AB, as Chief Executive Officer, Promimic AB, as Director, Xspray Pharma AB, as Director, Pharmacia Upjohn, as Project Director, Novozymes Biopharma Sweden AB, as Director-Product Pipeline & Business Development, BioChromix Pharma AB, as Non-Executive Director, Umecrine Cognition AB, as Director & Head-Business Development, Limone AB, as Director, NeoDynamics AB, as Director, OssDsign AB, as Director, KD Incentive AB, as Director, Modus Therapeutics Holding AB, as Director, Ziccum AB, as Deputy Director, AB Wilhelm Becker, as Project Manager, Karolinska Development AB (Private Equity), as Vice President from 2012 to 2014, Kabi Pharmacia, as Project Manager, Karolinska Development AB, as Vice President-Portfolio Management from 2007 to 2012, and Inhalation Sciences Sweden AB, as Chief Financial Officer.
Mr. Skolling received his graduate degree from Royal Institute of Technology.
Posizioni attive di Sten Gunnar Otto Skolling
| Società | Posizione | Inizio |
|---|---|---|
| ASARINA PHARMA AB | Public Communications Contact | - |
| NANEXA AB | Corporate Officer/Principal | 01/01/2015 |
| LIPIDOR AB | Director/Board Member | 01/01/2020 |
| CHORDATE MEDICAL HOLDING AB | Director/Board Member | 01/05/2023 |
| Bactaviva AB | Director/Board Member | - |
| Isles of Wines AB | Chief Executive Officer | - |
| Pharmor AB | Chief Executive Officer | - |
| Stockholm Biotechbuilders Association | Director/Board Member | - |
Biochromix AB
 Biochromix AB Medical SpecialtiesHealth Technology BioChromix AB manufactures diagnostic products. It is a company in the life science arena that develops and commercializes products for early stage diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The firm’s methods are based on their novel and patented Luminescent Conjugated Polymer (LCP) molecules. The company is headquartered in Solna, Sweden. | Director/Board Member | - |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Precedenti posizioni note di Sten Gunnar Otto Skolling
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░░░░░ ░░░░░░░░░░░ ░░ ░░░░░░░░ ░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - |
| ░░░░ ░░░░ ░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Formazione di Sten Gunnar Otto Skolling
| Royal Institute of Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 12 |
|---|---|
| PROMIMIC AB | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| LIPIDOR AB | Commercial Services |
| ASARINA PHARMA AB | Health Technology |
| NEOS AB | Health Technology |
| KAROLINSKA DEVELOPMENT AB | Finance |
| INHALATION SCIENCES SWEDEN AB | Health Technology |
| OSSDSIGN AB | Health Technology |
| MODUS THERAPEUTICS HOLDING AB | Health Technology |
| NANEXA AB | Health Technology |
| CHORDATE MEDICAL HOLDING AB | Health Technology |
| ZICCUM AB | Health Technology |
| Aziende private | 19 |
|---|---|
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
AB Wilhelm Becker
 AB Wilhelm Becker Chemicals: SpecialtyProcess Industries AB Wilhelm Becker operates as a holding company with interests in chemical companies. It manufactures industrial coatings for metals and plastics, and products for surface treatment of wood. The company is headquartered in Hoganas, Sweden. | Process Industries |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
Umecrine AB
 Umecrine AB BiotechnologyHealth Technology Umecrine AB provides pharmaceuticals against mental and physical symptoms. It develops antagonists to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. The company was founded by Carl Torbjörn Bäckström in 2000 and is headquartered in Umea, Sweden. | Health Technology |
| Kabi Pharmacia | |
| Pharmacia Upjohn | |
| KCIF Fund Management AB | |
Novozymes Biopharma Sweden AB
 Novozymes Biopharma Sweden AB BiotechnologyHealth Technology Part of Repligen Corp., Novozymes Biopharma Sweden AB operates as a contract manufacturer of biological products. The private company is based in Lund, Sweden. The CEO of the Swedish company is Harald Skogman. Novozymes Biopharma Sweden was acquired by Repligen Corp. from Novozymes A/S on December 20, 2011 for $29.02 million. | Health Technology |
Biochromix AB
Biochromix AB Medical SpecialtiesHealth Technology BioChromix AB manufactures diagnostic products. It is a company in the life science arena that develops and commercializes products for early stage diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The firm’s methods are based on their novel and patented Luminescent Conjugated Polymer (LCP) molecules. The company is headquartered in Solna, Sweden. | Health Technology |
BioChromix Pharma AB
 BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services BioChromix Pharma AB was founded as a subsidiary to BioChromix AB. The Company is a pharmaceutical company active in research and development of novel treatments for neurodegenerative disorders based on its proprietary technology for therapeutics. Current research and development is focused on the indication area of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. BioChromix Pharma is performing pre-clinical development but is looking to reach the clinical phase within the coming years. Alzheimer's disease is the most common neurodegenerative disease, affecting around 25 million people and the costs associated with AD are tremendous. At the moment, there are no efficient treatments for AD but there are clinical trials are ongoing and some are focused at reducing the levels of the neurotoxic Aß peptide. The portfolio of the company includes a number of newly discovered lead compounds that are under investigation. | Commercial Services |
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Health Technology |
Limone AB
 Limone AB Pharmaceuticals: MajorHealth Technology Limone is developing new treatments for cancer. The target is the protein LL37 recently reported to act as a growth factor for cancer cells in various cancer indications. Limone has a patent estate covering LL37 and is actively looking for a partner to develop this therapeutic concept. | Health Technology |
| Venture Cup Ost | |
| KD Incentive AB | |
| Stockholm Biotechbuilders Association | |
RespiNor AS
 RespiNor AS Electronic Equipment/InstrumentsElectronic Technology RespiNor AS operates as a medical device company. The company is headquartered in Oslo, Norway. | Electronic Technology |
| Pharmor AB | |
| Isles of Wines AB | |
| Bactaviva AB |
- Borsa valori
- Insiders
- Sten Gunnar Otto Skolling
